Literature DB >> 18949358

Estrogen and progestin regulate metastasis through the PI3K/AKT pathway in human ovarian cancer.

Keqin Hua1, Weiwei Feng, Qi Cao, Xianrong Zhou, Xin Lu, Youji Feng.   

Abstract

Estrogen and progestin are involved in ovarian carcinogenesis. Change in nm23-H1 expression and the PIK3/AKT pathway are involved in carcinogenesis, development, invasion and metastasis of ovarian cancers. Therefore, it is critical to understand the signaling pathways that regulate hormone-induced cell migration and invasion in ovarian cancer. We investigated nm23-H1, AKT and pAKT expression by using immunohistochemical staining in ovarian clear cell adenocarcinoma, ovarian benign, borderline and malignant serous tumors and analyzed their relationship with prognostic factors. Using ES-2 and SKOV-3 ovarian cancer cell lines, we studied the modulation of estrogen and progestin on cell migration and invasion as well as their effect on AKT, pAKT and nm23-H1 expression. Furthermore, the signaling pathways were examined using pharmacological inhibitors (LY294002 and PD98059) or AKT siRNA combined with estrogen or progestin in the two cell lines. Weak nm23-H1 and high AKT and pAKT expression was observed in ovarian serous adeno-carcinoma and ovarian clear cell adenocarcinoma. Our data demonstrated that the expression of nm23-H1 was negatively correlated with tumor stage and grade and lymph node metastasis, whereas the expression of AKT/pAKT was positively correlated with these clinic factors. Estrogen up-regulated pAKT expression and reduced nm23-H1 expression, which ultimately resulted in increased cell migration and invasion. In contrast, progestin reduced pAKT expression and increased nm23-H1 expression, which inhibited cell migration. PIK3 kinase inhibitor LY294002 antagonized the effect of estrogen. On the other hand, it reinforced the effect of progestin. Our data suggest that AKT and pAKT are unfavorable prognostic factors for ovarian serous adenocarcinoma and clear cell carcinomas whereas nm23-H1 expression predicates favorable patient prognosis. Estrogen down-regulates nm23-H1 expression and promotes cell migration and invasion by activating the PIK3/AKT pathway. Progestin has an opposing effect.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18949358

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  17 in total

1.  A literature mining-based approach for identification of cellular pathways associated with chemoresistance in cancer.

Authors:  Jung Hun Oh; Joseph O Deasy
Journal:  Brief Bioinform       Date:  2015-07-27       Impact factor: 11.622

Review 2.  Estrogen signaling crosstalk: Implications for endocrine resistance in ovarian cancer.

Authors:  Jennifer R Ribeiro; Richard N Freiman
Journal:  J Steroid Biochem Mol Biol       Date:  2014-02-22       Impact factor: 4.292

Review 3.  Diagnosis, treatment, and follow-up of borderline ovarian tumors.

Authors:  Daniela Fischerova; Michal Zikan; Pavel Dundr; David Cibula
Journal:  Oncologist       Date:  2012-09-28

4.  The role of the PTEN/PI3K/Akt pathway on prognosis in epithelial ovarian cancer: a meta-analysis.

Authors:  Jing Cai; Linjuan Xu; Huijuan Tang; Qiang Yang; Xiaoqing Yi; Yan Fang; Ying Zhu; Zehua Wang
Journal:  Oncologist       Date:  2014-04-09

5.  Single nucleotide variants in metastasis-related genes are associated with breast cancer risk, by lymph node involvement and estrogen receptor status, in women with European and African ancestry.

Authors:  Michelle R Roberts; Lara E Sucheston-Campbell; Gary R Zirpoli; Michael Higgins; Jo L Freudenheim; Elisa V Bandera; Christine B Ambrosone; Song Yao
Journal:  Mol Carcinog       Date:  2016-09-21       Impact factor: 4.784

6.  Steroid hormone synthesis by the ovarian stroma surrounding epithelial ovarian tumors: a potential mechanism in ovarian tumorigenesis.

Authors:  Luis Z Blanco; Elisabetta Kuhn; Jane C Morrison; Asli Bahadirli-Talbott; Anne Smith-Sehdev; Robert J Kurman
Journal:  Mod Pathol       Date:  2017-01-06       Impact factor: 7.842

7.  The effects of 17β-estradiol and a selective estrogen receptor modulator, bazedoxifene, on ovarian carcinogenesis.

Authors:  Iris L Romero; WooSeok Lee; Anirban K Mitra; Ilyssa O Gordon; Yan Zhao; Payton Leonhardt; Carla V Penicka; Keeley L Mui; Thomas N Krausz; Geoffrey L Greene; Ernst Lengyel
Journal:  Gynecol Oncol       Date:  2011-10-11       Impact factor: 5.482

Review 8.  Hormone response in ovarian cancer: time to reconsider as a clinical target?

Authors:  Francesmary Modugno; Robin Laskey; Ashlee L Smith; Courtney L Andersen; Paul Haluska; Steffi Oesterreich
Journal:  Endocr Relat Cancer       Date:  2012-11-09       Impact factor: 5.678

9.  Estradiol-mediated tumor neo-vascularization.

Authors:  Shilpi Rajoria; Robert Suriano; Yushan L Wilson; Andrea L George; Jan Geliebter; Stimson P Schantz; Raj K Tiwari
Journal:  Oncol Lett       Date:  2011-03-21       Impact factor: 2.967

10.  Effects of Estrogen on Cardiac mRNA and LncRNA Expression Profiles in Hypertensive Mice.

Authors:  Jingkang Zhu; Huan Wang; Hui Chen
Journal:  J Cardiovasc Transl Res       Date:  2020-03-31       Impact factor: 4.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.